Comparison of Serum Lipid Profile in Diabetics With and Without Symptoms of Peripheral Neuropathy

Dr. Suneetha. G¹, Dr. Satyanarayana Prasad. A²
¹Assistant Professor of Physiology, NRI MC & GH, Chinakakani, Guntur (Dt), AP, INDIA-522503;
²Senior Resident, Department of General Surgery, NRI MC & GH, Chinakakani, Guntur (Dt), AP.
*Corresponding author: * Dr Suneetha. G

Abstract: The pathogenesis of neuropathy in type 2 diabetes mellitus is multifactorial. This study is aimed to assess any association of dyslipidemias with peripheral neuropathy in type 2 diabetes mellitus. It also reveals any difference in lipid profile between asymptomatic (without symptoms of peripheral neuropathy) and symptomatic (with symptoms of peripheral neuropathy) subjects of diabetes mellitus.

Key words: Type 2 Diabetes mellitus, DPN, DN, Dyslipidemias, HbA₁c.

I. Introduction

Diabetes mellitus is a major public health problem worldwide. The World Health Organization has estimated that, the number of adults with diabetes in the world would increase alarmingly from 135 million in 1995 to 300 million in 2025¹. Type 2 diabetes, which is more than 90% of all diabetic cases, affects 5.9% of the world’s adult population with almost 80% of the total in developing countries². India leads the world with largest number of diabetic subjects earning the dubious distinction of being termed the “diabetes capital of the world”³.

The so called “Asian Indian Phenotype” refers to certain unique clinical and biochemical abnormalities in Indians which include increased insulin resistance, greater abdominal adiposity i.e., higher waist circumference despite lower body mass index, lower adiponectin and higher high sensitive C-reactive protein levels. At least a part of this is due to genetic factors. This term refers to the peculiar metabolic features of Asian Indians characterized by a propensity to excess visceral adiposity, dyslipidemia with low HDL cholesterol, elevated serum triglycerides and increased small, dense LDL cholesterol, and an increased ethnic (possibly genetic) susceptibility to diabetes and premature coronary artery disease. However, the primary driver of the epidemic of diabetes is the rapid epidemiological transition associated with changes in dietary patterns and decreased physical activity as evident from the higher prevalence of diabetes in the urban population. The most disturbing trend is the shift in age of onset of diabetes to an younger age in the recent years, having long lasting adverse effects on nation’s health and economy.

Genetic predisposition combined with lifestyle changes, associated with urbanization and globalization, contribute to this rapid rise of diabetes in India⁴. It is known that almost 50% of people with diabetes remain undetected and hence some may even present with micro vascular and macro vascular complications at the time of diagnosis⁵,⁶. Chronic peripheral sensory motor symmetrical neuropathy (DPN) accounts for approximately 75% of the diabetic neuropathies⁷. It is defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes mellitus, after exclusion of other causes⁸. The primary symptom of DPN is loss of sensation in the toes, which extends to involve the feet and leg in a stocking distribution. Some patients complain about numbness and pain, but the disease progresses most frequently insidiously and undetected. If no action is taken, foot callus, ulceration and infection might develop and further turn into distressing and painful impairment. The foot ulcers in diabetic patients mostly of neuropathic origin, and therefore eminently preventable⁹. Age, duration of diabetes and poor glycaemic control are recognised as risk factors for DPN, while cigarette smoking, hypertension, obesity, hyperlipidaemia and microalbuminuria has been pointed as potential risk indicators⁹. Although DPN may be asymptomatic and insidious in onset, neuropathic sensory symptoms may be complaints presented by the patient to the physician; therefore, they are clinically important.

MoazA et. al, reported that the diabetic neuropathy was significantly associated with age, duration of disease, negative association with arterial blood pressure, smoking status, low HDL cholesterol level, high triglyceride level, BMI and HbA₁c⁹. So there are conflicting reports pertaining to role of duration, dyslipidaemias, HbA₁c levels as causative factors of diabetic neuropathy. Against this backdrop the present study is intended to compare the levels of HbA₁c and lipid profile between asymptomatic and symptomatic diabetic patients for neuropathy.
II. Materials & Methods

**Study Design:** A total number of 104 diabetic patients were selected for study. Out of them 52 subjects were symptomatic for neuropathy (symptomatic) and 52 subjects were asymptomatic for neuropathy (asymptomatic).

**Study Setting:** N.R.I. MEDICAL COLLEGE & G.H. Chinakakani, Guntur, Andhra Pradesh.

For diagnosis of DN, bedside examination should include assessment of muscle power, sensations of pinprick, joint position, touch, and temperature. Vibration test should be done by tuning fork of a 128 Hz. For touch sensation mono filament of 10-g is recommended. Sensory examination should be performed on hands and feet bilaterally. The relevant laboratory parameters such as FBS, HbA1c, lipid profile were done in 52 diabetic subjects with symptoms and signs of neuropathy and 52 diabetic subjects without such symptoms and signs. The procedure was explained to all the subjects and written consent was obtained and was cleared by the institutional ethics committee. Standard test procedures were employed to collect the following laboratory data.

**Protocol for Biochemical parameters**
2. Glucose by Hexokinase method on Dade dimensions – Seimens with reference range of 74 – 106 mg/dl.
3. Triglycerides by Lipase / G – 01 Dehydrogenase method on Dade dimensions – Seimens with reference range of < 150 mg/dl.
5. HDL by direct Non – Immunological method on Dade dimensions – Seimens with reference range of 35 – 60 mg/dl.
6. LDL Cholesterol is derived by calculation using Friedwald’s formula.

All the above parameters before analysis were calibrated and the IQC is within ± 1 S.D

**STATISTICAL ANALYSIS:** The collected data were tabulated (mean ± S.D) in 2 categories. Results of mean age, mean duration, Fasting Blood Sugar (FBS), HbA1C and lipid profile are statistically compared between the two groups using student unpaired ‘t’- test. A ‘p’ value of <0.05 was considered significant.

### III. Results

**Table 1:** Age wise stratification of diabetic patients – Asymptomatic and symptomatic for neuropathy:

<table>
<thead>
<tr>
<th>Age (yrs)</th>
<th>No. of asymptomatic patients for neuropathy (%)</th>
<th>No. of symptomatic patients for neuropathy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>40 to 50</td>
<td>8 (15.39)</td>
<td>23 (44.23)</td>
</tr>
<tr>
<td>51 to 60</td>
<td>24 (46.15)</td>
<td>11 (21.15)</td>
</tr>
<tr>
<td>61 to 70</td>
<td>16 (30.77)</td>
<td>11 (21.15)</td>
</tr>
<tr>
<td>71 to 80</td>
<td>4 (7.69)</td>
<td>7 (13.46)</td>
</tr>
<tr>
<td>Mean age ± SD</td>
<td>59.15 ± 8.95</td>
<td>56.13 ± 12.18</td>
</tr>
</tbody>
</table>

**Table 2:** Duration of diabetes since first identified among study subjects

<table>
<thead>
<tr>
<th>Duration</th>
<th>No. of asymptomatic patients for neuropathy (%)</th>
<th>No. of symptomatic patients for neuropathy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5yrs</td>
<td>16 (30.77)</td>
<td>14 (26.92)</td>
</tr>
<tr>
<td>5-10yrs</td>
<td>34 (65.38)</td>
<td>35 (67.31)</td>
</tr>
<tr>
<td>&gt;10yrs</td>
<td>2 (3.85)</td>
<td>3 (5.77)</td>
</tr>
<tr>
<td>Mean duration ± SD</td>
<td>5.73 ± 2.24</td>
<td>6.27 ± 2.37</td>
</tr>
</tbody>
</table>

**Table 3:** Comparison of biochemical parameters as mean values between asymptomatic and symptomatic groups.

<table>
<thead>
<tr>
<th>Biochemical parameters</th>
<th>Asymptomatic diabetes patients Mean±SD (n=52)</th>
<th>Symptomatic diabetes patients Mean±SD (n=52)</th>
<th>‘p’ value</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1C (%)</td>
<td>7.82 ± 0.81</td>
<td>7.60 ± 0.90</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>FBS (mg/dl)</td>
<td>186.62±36.14</td>
<td>184.87±35.99</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>
Table 4: Comparison of lipid profile and lipid ratios as mean values between asymptomatic and symptomatic groups.

<table>
<thead>
<tr>
<th>Biochemical parameters</th>
<th>Asymptomatic diabetes patients Mean±SD (n=52)</th>
<th>Symptomatic diabetes patients Mean±SD (n=52)</th>
<th>'p' value</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC (mg/dl)</td>
<td>196.69 ± 39.18</td>
<td>189.07± 31.9</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>STGL (mg/dl)</td>
<td>174.23 ± 61.83</td>
<td>156.01±60.59</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>SLDL (mg/dl)</td>
<td>127.77 ± 25.47</td>
<td>128.4± 23.03</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>32.19 ± 3.05</td>
<td>30.27± 2.88</td>
<td>0.005</td>
</tr>
<tr>
<td>TC/LDL</td>
<td>1.54 ± 0.08</td>
<td>6.27 ± 1.13</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TC/HDL</td>
<td>6.13 ± 1.20</td>
<td>1.47 ± 0.09</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>TG/HDL</td>
<td>5.42 ± 1.88</td>
<td>5.14 ± 1.99</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>LDL/HDL</td>
<td>3.98 ± 0.78</td>
<td>4.27 ± 0.86</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

IV. Discussion

The cause of DN though remains unknown but ischaemic and metabolic components are implicated. Hyperglycaemia induces rheological changes, which increases endothelial vascular resistance and reduces nerve blood flow. Hyperglycaemia also causes depletion of nerve myoinositol through a competitive uptake mechanism. Moreover, activation of polyol pathway in the nerve through enzyme aldose reductase leads to accumulation of sorbitol and fructose in the nerve and induces non-enzymatic glycosylation of structural nerve proteins. Hyperglycaemia also induces oxidative stress. Activation of protein kinase C has been linked to vascular damage in DN. These changes result in abnormal neuronal, axonal, and Schwann cell metabolism, which result in impaired axonal transport. Direct measurement of glucose, sorbitol, and fructose in nerves of diabetic patients showed correlation with the severity of neuropathy. Endoneural hypoxia is produced by increased vascular resistance and reduced blood flow in the nerve. Hypoxia leads to further capillary damage, which in turn aggravates disturbance in axonal transport and reduced Na-K ATPase activity leading to axonal atrophy and impairment of nerve conduction. Unfortunately the basic research in DN has focused on carbohydrate metabolism; whereas amino acids, electrolytes, and lipid biochemical changes, which are associated with DM, have not been investigated with same vigour.

Complications of type 2 diabetes: Microvascular complications include nephropathy, retinopathy, and neuropathy and macrovascular complications are primarily manifested by atherosclerosis and resulting cardiovascular morbidity and mortality. In both microvascular and macrovascular diabetic disease processes, the initial pathophysiological step is believed to be tissue damage caused by hyperglycemia-mediated mitochondrial superoxide overproduction. However, from there, the mechanisms differ. The primary disease mechanism in diabetic macrovascular disease is atherosclerosis. Atherosclerosis is believed to begin with arterial wall injury, leading to chronic inflammation and immune cell infiltration, lipid deposition from low-density lipoprotein particles, and subsequent smooth muscle proliferation. The result is a fatty atherosclerotic lesion with a fibrous cap, that, when ruptured, may cause infarction. In addition to the formation of atherosclerotic lesions, evidence suggests both increased platelet activity as well as a hypercoagulable state in type 2 diabetes. All of these factors increase the risk of thrombosis or thromboembolism.

The mechanisms of action underlying diabetic microvascular disease do not involve atherosclerosis. Cells damaged by the aforementioned hyperglycemia-induced superoxide toxicity include those in the renal glomerulus, retina, and peripheral nerves. These cells are at increased risk because they are unable to regulate uptake of glucose in the hyperglycemic setting. Over a period of time, the result of such continued toxicity is nephropathy, retinopathy, and peripheral neuropathy. Measuring more downstream disease processes, such as superoxide activity, has the potential to refine our ability to identify patients at elevated risk for complications of type 2 diabetes.

In our study mean age of symptomatics is 56 years while that of asymptomatics is 59 years. In 23 out of 52 i.e 44.23% of symptomatic subjects onset was early between 40 – 50 years as shown in table – 1. Symptoms of PN manifested at a significantly lower age in our study. This is in agreement with Vondrova and coworkers in Czech, who found that diabetic polyneuropathy manifested at a younger age. The mean duration of diabetics in both cases was between 5-10 years since first diagnosed as shown in table – 2. Expectedly both
groups had high fasting blood sugar levels of comparable degree. The mean values as shown in table – 3 are 186.62±36.14 mg/dl for asymptomatic subjects and 184.87±35.59 mg/dl for symptomatic subjects.

At the outset bed side neurological examination was carried out in all the subjects under study. Invariably neurological signs such as sluggish ankle jerk, gait disturbance, impaired vibration sense and other sensory defects were found in symptomatic patients. Asymptomatic subjects didn’t reveal clinical signs of neurological deficiency. Biochemical parameters of both glycemic indicators and lipid profiles were estimated as shown in table – 3 and 4. HbA1C represents a carbohydrate moiety attached to small portion of haemoglobin. It has many distinct fractions A1a, A1b, A1c. But A1c fraction accounts for 60% of bond glucose and hence the significance of its estimation. Non diabetic individuals were said to have HbA1C values in the range of 3 – 6% 15. Dysglycosylated haemoglobin was estimated in all the subjects to evaluate the degree of glycemic control for the last 2 – 3 months. It is because in sustained hyperglycemia of long standing, the proportion of HbA1c increases. Chronic hyperglycemia is said to promote diabetic neuropathy by varied mechanisms such as increased oxidative stress, decreased nitric oxide, impaired endothelial function16. The amount of glycosylated haemoglobin also correlates well with fasting and postprandial glucose levels17. The table – 3 reveals poor glycemic control in almost equal measure in both the groups as indicated by elevated levels of HbA1C i.e. 7.82 ± 0.81 in asymptomatic subjects and 7.06 ± 0.09 in symptomatic subjects and elevated levels of FBS 186.62 ± 36.14 mg/dl in asymptomatic group and 184.87 ± 35.99 mg/dl in symptomatic group. As per a “research group” report in 1993, improved glycemic control has been shown to prevent and delay progression of diabetic neuropathy emphasizing the importance of early diagnosis and aggressive management in these patients 18.

The fasting serum lipid levels in asymptomatic and symptomatic patients of diabetic neuropathy were analyzed and shown in table – 4. National Cholesterol Education Programme (NCEP) 19 had given certain guidelines defining normal limits of lipid levels. The value of Total Cholesterol (TC) exceeding 200mg/dl is defined as hypercholesterolemia. Like wise LDL value exceeding 100mg/dl and triglycerides (TGL) exceeding 150mg/dl are abnormal. But HDL value of <40mg/dl is unfavorable index of lipid profile. Dyslipidaemia was defined as by the presence of one or more abnormal serum lipid concentrations deviating from above values 19. The significant features of lipid profile in table – 4 are elevated levels of STGL, SLDL & decline in HDL representing dyslipidaemia in both asymptomatic and symptomatic groups. Of these the decline in HDL is statistically significant between the two groups, ‘p’ value being 0.005 influenced by a great decline in symptomatic group. Their role in the causation of neuropathic symptoms needs further investigation. Interestingly total cholesterol in both cases is close to upper limit, particularly in asymptomatic diabetic patients. There is a statistically significant difference between TC / LDL & TC / HDL ratios between the two groups. The variations in the ratios are on account of taking individual sample ratios in both groups rather than total mean ratios. Hence it is difficult to draw conclusions for the group as a whole from these ratios.

Diabetic dyslipidaemia is often associated with elevated triglycerides, LDL, total cholesterol and decreased HDL. Except for TC in our study all the three lipids are changing in abnormal direction. According to Bener A, Zirie M, hypertryglycerideremia is said to be the most common alteration of lipoproteins in type-II diabetes mellitus20. According to their postulation it is caused by hyperglycemia and insulin resistance by a variety of mechanisms such as over production of VLDL, TGL and defective clearance of VLDL, TGL and decreased activity of lipoprotein lipase and decreased production of apolipoprotein B. Also it was postulated that increased proportion of cholesterol, as a result of altered VLDL composition, increases the propensity for atherosclerosis13. Increased LDL is explained either by increased LDL production or decreased LDL clearance. Mild hyperglycemia is said to increase LDL production, while insulin resistance or relative insulin deficiency causes defects in LDL clearance. Increased susceptibility of LDL for oxidation is also said to play a major role in atherosclerotic process 15. Regarding HDL, hyperglycemia causes increased activity of hepatic lipase which increases the clearance of HDL. While impaired catabolism of VLDL causes decreased formation of HDL 15. This is said to be the reason for decreased levels of HDL in type-II diabetes mellitus15.

Chintamani Bodheet et al, found a link between dyslipidaemia and higher levels of Hba1c values 17. There is no such association is found in our study. The ultimate analysis can be summarized that STGL and HDL cholesterol and ratio of TG/HDL reflect the balance between atherogenic and protective lipoproteins. There were no significant relation between diabetic neuropathy with sex and hyperlipidemia which is in agreement with the findings of Hillson et al22 and Master et al 22. According to a research group, lipid profile (total serum cholesterol, HDL & LDL cholesterol, fasting triglyceride) not effect the prevalence of peripheral neuropathy23. In our study also, there is no significant statistical difference in lipid profile except HDL, between asymptomatics and symptomatics for neuropathy.

V. Conclusion

There is no significant difference in lipid profile, between asymptomatics and symptomatics for peripheral neuropathy in diabetes except for HDL.

DOI: 10.9790/0853-1607021721 www.iosrjournals.org 20 | Page
But the ratio of total cholesterol to LDL cholesterol and total cholesterol to HDL cholesterol shows significant difference between asymptomatics and symptomatics.

So there is no significant relation between Diabetic neuropathy with dyslipidemias and sex. However, significantly high levels of HDL was observed in asymptomatic patients which need further studies to ponder the probable protective role of HDL cholesterol.

References
